Securing America’s Pharmaceutical Supply Chain Act

Summary

Securing America's Pharmaceutical Supply Chain Act This bill allows an executive agency to purchase a drug approved or licensed by the Food and Drug Administration only if the drug is over 50% sourced, manufactured, and assembled in the United States. This requirement may be waived (1) if the drug is not available in sufficient quantity or quality as over 50% sourced, manufactured, and assembled in the United States; or (2) during an emergency. The U.S. Trade Representative (USTR) shall modify U.S. product coverage under all free trade agreements and the World Trade Organization Agreement on Government Procurement to exclude coverage of essential medicines and medical countermeasures. Subsequent to such modifications, the USTR shall make any necessary corresponding modifications of existing waivers and notify the Office of Management and Budget.

This text is taken from the official record. PoliticalRepo does not editorialize.

Timeline

No timeline events have been ingested for this record yet.

Votes

No vote records are attached yet.

Versions

No version snapshots stored. Document URLs remain at the source.

Documents

3 official files

• Introduced in House (text)

  Introduced in House · EN · 1 June 2021

  ViewDownloadOpen at official source

• Introduced in House (PDF)

  Introduced in House · EN · 1 June 2021

  ViewDownloadOpen at official source

• Introduced in House

  summary · EN · 1 June 2021

  Open at official source

Sponsors

No sponsors or actors listed by the source.

Related records

No cross-record relationships stored yet.